SARTORIUS AG-VORZUG (SRT3.DE) Stock Fundamental Analysis

FRA:SRT3 • DE0007165631

239 EUR
+7.5 (+3.24%)
Last: Feb 20, 2026, 05:36 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership
Fundamental Rating

2

SRT3 gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 18 industry peers in the Life Sciences Tools & Services industry. Both the profitability and financial health of SRT3 have multiple concerns. SRT3 is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

3

1. Profitability

1.1 Basic Checks

  • In the past year SRT3 was profitable.
  • In the past year SRT3 had a positive cash flow from operations.
  • SRT3 had positive earnings in 4 of the past 5 years.
  • Of the past 5 years SRT3 4 years had a positive operating cash flow.
SRT3.DE Yearly Net Income VS EBIT VS OCF VS FCFSRT3.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

1.2 Ratios

  • Looking at the Return On Assets, with a value of 1.39%, SRT3 is doing worse than 77.78% of the companies in the same industry.
  • SRT3 has a worse Return On Equity (5.01%) than 72.22% of its industry peers.
  • SRT3 has a worse Return On Invested Capital (4.71%) than 77.78% of its industry peers.
  • The Average Return On Invested Capital over the past 3 years for SRT3 is in line with the industry average of 9.63%.
Industry RankSector Rank
ROA 1.39%
ROE 5.01%
ROIC 4.71%
ROA(3y)4.22%
ROA(5y)4.59%
ROE(3y)15.69%
ROE(5y)18.55%
ROIC(3y)8.34%
ROIC(5y)10.45%
SRT3.DE Yearly ROA, ROE, ROICSRT3.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 10 20 30

1.3 Margins

  • Looking at the Profit Margin, with a value of 3.80%, SRT3 is doing worse than 77.78% of the companies in the same industry.
  • SRT3's Profit Margin has declined in the last couple of years.
  • With a Operating Margin value of 14.06%, SRT3 perfoms like the industry average, outperforming 50.00% of the companies in the same industry.
  • In the last couple of years the Operating Margin of SRT3 has declined.
  • SRT3's Gross Margin of 46.48% is fine compared to the rest of the industry. SRT3 outperforms 66.67% of its industry peers.
  • SRT3's Gross Margin has declined in the last couple of years.
Industry RankSector Rank
OM 14.06%
PM (TTM) 3.8%
GM 46.48%
OM growth 3Y-21.14%
OM growth 5Y-7.77%
PM growth 3Y-35.47%
PM growth 5Y-21.95%
GM growth 3Y-5.43%
GM growth 5Y-2.63%
SRT3.DE Yearly Profit, Operating, Gross MarginsSRT3.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 10 20 30 40 50

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

1

2. Health

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so SRT3 is still creating some value.
  • SRT3 has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
SRT3.DE Yearly Shares OutstandingSRT3.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
SRT3.DE Yearly Total Debt VS Total AssetsSRT3.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B 8B 10B

2.2 Solvency

  • An Altman-Z score of 2.41 indicates that SRT3 is not a great score, but indicates only limited risk for bankruptcy at the moment.
  • SRT3 has a Altman-Z score (2.41) which is in line with its industry peers.
  • SRT3 has a debt to FCF ratio of 8.92. This is a slightly negative value and a sign of low solvency as SRT3 would need 8.92 years to pay back of all of its debts.
  • With a Debt to FCF ratio value of 8.92, SRT3 is not doing good in the industry: 66.67% of the companies in the same industry are doing better.
  • A Debt/Equity ratio of 1.28 is on the high side and indicates that SRT3 has dependencies on debt financing.
  • SRT3's Debt to Equity ratio of 1.28 is on the low side compared to the rest of the industry. SRT3 is outperformed by 77.78% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.28
Debt/FCF 8.92
Altman-Z 2.41
ROIC/WACC0.57
WACC8.29%
SRT3.DE Yearly LT Debt VS Equity VS FCFSRT3.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B 4B 5B

2.3 Liquidity

  • A Current Ratio of 0.95 indicates that SRT3 may have some problems paying its short term obligations.
  • Looking at the Current ratio, with a value of 0.95, SRT3 is doing worse than 83.33% of the companies in the same industry.
  • A Quick Ratio of 0.49 indicates that SRT3 may have some problems paying its short term obligations.
  • SRT3 has a Quick ratio of 0.49. This is amonst the worse of the industry: SRT3 underperforms 88.89% of its industry peers.
Industry RankSector Rank
Current Ratio 0.95
Quick Ratio 0.49
SRT3.DE Yearly Current Assets VS Current LiabilitesSRT3.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. Growth

3.1 Past

  • SRT3 shows a small growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 1.76% yearly.
EPS 1Y (TTM)N/A
EPS 3Y-20.66%
EPS 5Y1.76%
EPS Q2Q%21.15%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%2.29%

3.2 Future

  • Based on estimates for the next years, SRT3 will show a quite strong growth in Earnings Per Share. The EPS will grow by 15.97% on average per year.
  • Based on estimates for the next years, SRT3 will show a quite strong growth in Revenue. The Revenue will grow by 8.68% on average per year.
EPS Next Y26.59%
EPS Next 2Y23.47%
EPS Next 3Y20.79%
EPS Next 5Y15.97%
Revenue Next Year7.13%
Revenue Next 2Y8.81%
Revenue Next 3Y9.38%
Revenue Next 5Y8.68%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
SRT3.DE Yearly Revenue VS EstimatesSRT3.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 2B 4B 6B
SRT3.DE Yearly EPS VS EstimatesSRT3.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 5 10

More info and screens

Find the best growth stocksShow best growing peers

1

4. Valuation

4.1 Price/Earnings Ratio

  • With a Price/Earnings ratio of 50.00, SRT3 can be considered very expensive at the moment.
  • Based on the Price/Earnings ratio, SRT3 is valued expensively inside the industry as 83.33% of the companies are valued cheaper.
  • SRT3's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 26.99.
  • With a Price/Forward Earnings ratio of 39.50, SRT3 can be considered very expensive at the moment.
  • 77.78% of the companies in the same industry are cheaper than SRT3, based on the Price/Forward Earnings ratio.
  • The average S&P500 Price/Forward Earnings ratio is at 28.02. SRT3 is valued slightly more expensive when compared to this.
Industry RankSector Rank
PE 50
Fwd PE 39.5
SRT3.DE Price Earnings VS Forward Price EarningsSRT3.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, SRT3 is valued a bit more expensive than 61.11% of the companies in the same industry.
  • SRT3's Price/Free Cash Flow is on the same level as the industry average.
Industry RankSector Rank
P/FCF 37.39
EV/EBITDA 23.5
SRT3.DE Per share dataSRT3.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 20 -20 40

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
  • SRT3's earnings are expected to grow with 20.79% in the coming years. This may justify a more expensive valuation.
PEG (NY)1.88
PEG (5Y)28.36
EPS Next 2Y23.47%
EPS Next 3Y20.79%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

4

5. Dividend

5.1 Amount

  • With a yearly dividend of 0.38%, SRT3 is not a good candidate for dividend investing.
  • Compared to an average industry Dividend Yield of 0.44, SRT3 has a dividend in line with its industry peers.
  • Compared to an average S&P500 Dividend Yield of 1.81, SRT3's dividend is way lower than the S&P500 average.
Industry RankSector Rank
Dividend Yield 0.38%

5.2 History

  • The dividend of SRT3 has a limited annual growth rate of 3.71%.
Dividend Growth(5Y)3.71%
Div Incr Years0
Div Non Decr Years0

5.3 Sustainability

  • 37.92% of the earnings are spent on dividend by SRT3. This is a low number and sustainable payout ratio.
  • SRT3's earnings are growing more than its dividend. This makes the dividend growth sustainable.
DP37.92%
EPS Next 2Y23.47%
EPS Next 3Y20.79%
SRT3.DE Yearly Income VS Free CF VS DividendSRT3.DE Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M
SRT3.DE Dividend Payout.SRT3.DE Dividend Payout, showing the Payout Ratio.SRT3.DE Dividend Payout.PayoutRetained Earnings

More info and screens

Find the best dividend stocksShow peers with best dividend

SARTORIUS AG-VORZUG

FRA:SRT3 (2/20/2026, 5:36:15 PM)

239

+7.5 (+3.24%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)02-03
Earnings (Next)04-23
Inst Owners4.42%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap17.90B
Revenue(TTM)N/A
Net Income(TTM)133.70M
Analysts80
Price Target381.28 (59.53%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0.38%
Yearly Dividend0.74
Dividend Growth(5Y)3.71%
DP37.92%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-2.85%
Min EPS beat(2)-10.52%
Max EPS beat(2)4.83%
EPS beat(4)1
Avg EPS beat(4)-3.47%
Min EPS beat(4)-10.52%
Max EPS beat(4)4.83%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)0.05%
Min Revenue beat(2)-0.73%
Max Revenue beat(2)0.83%
Revenue beat(4)3
Avg Revenue beat(4)1.91%
Min Revenue beat(4)-0.73%
Max Revenue beat(4)4.87%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-1.48%
PT rev (3m)11.4%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-3.33%
EPS NY rev (1m)0%
EPS NY rev (3m)0.4%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.96%
Revenue NY rev (1m)0.08%
Revenue NY rev (3m)-0.03%
Valuation
Industry RankSector Rank
PE 50
Fwd PE 39.5
P/S 5.09
P/FCF 37.39
P/OCF 20.47
P/B 6.71
P/tB N/A
EV/EBITDA 23.5
EPS(TTM)4.78
EY2%
EPS(NY)6.05
Fwd EY2.53%
FCF(TTM)6.39
FCFY2.67%
OCF(TTM)11.68
OCFY4.89%
SpS46.97
BVpS35.63
TBVpS-35.24
PEG (NY)1.88
PEG (5Y)28.36
Graham Number61.91
Profitability
Industry RankSector Rank
ROA 1.39%
ROE 5.01%
ROCE 6.33%
ROIC 4.71%
ROICexc 4.98%
ROICexgc 17.77%
OM 14.06%
PM (TTM) 3.8%
GM 46.48%
FCFM 13.61%
ROA(3y)4.22%
ROA(5y)4.59%
ROE(3y)15.69%
ROE(5y)18.55%
ROIC(3y)8.34%
ROIC(5y)10.45%
ROICexc(3y)8.77%
ROICexc(5y)11.17%
ROICexgc(3y)24.37%
ROICexgc(5y)31.52%
ROCE(3y)11.22%
ROCE(5y)14.06%
ROICexgc growth 3Y-35.26%
ROICexgc growth 5Y-11.95%
ROICexc growth 3Y-38.49%
ROICexc growth 5Y-19.53%
OM growth 3Y-21.14%
OM growth 5Y-7.77%
PM growth 3Y-35.47%
PM growth 5Y-21.95%
GM growth 3Y-5.43%
GM growth 5Y-2.63%
F-Score7
Asset Turnover0.37
Health
Industry RankSector Rank
Debt/Equity 1.28
Debt/FCF 8.92
Debt/EBITDA 3.69
Cap/Depr 92.32%
Cap/Sales 11.25%
Interest Coverage 2.65
Cash Conversion 94.72%
Profit Quality 357.97%
Current Ratio 0.95
Quick Ratio 0.49
Altman-Z 2.41
F-Score7
WACC8.29%
ROIC/WACC0.57
Cap/Depr(3y)148.03%
Cap/Depr(5y)150.65%
Cap/Sales(3y)13.71%
Cap/Sales(5y)12.64%
Profit Quality(3y)282.77%
Profit Quality(5y)224.27%
High Growth Momentum
Growth
EPS 1Y (TTM)N/A
EPS 3Y-20.66%
EPS 5Y1.76%
EPS Q2Q%21.15%
EPS Next Y26.59%
EPS Next 2Y23.47%
EPS Next 3Y20.79%
EPS Next 5Y15.97%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%2.29%
Revenue Next Year7.13%
Revenue Next 2Y8.81%
Revenue Next 3Y9.38%
Revenue Next 5Y8.68%
EBIT growth 1Y18.65%
EBIT growth 3Y-21.66%
EBIT growth 5Y4.31%
EBIT Next Year101.42%
EBIT Next 3Y38.38%
EBIT Next 5Y25.33%
FCF growth 1Y123.33%
FCF growth 3Y7.25%
FCF growth 5Y29.73%
OCF growth 1Y6.61%
OCF growth 3Y4.07%
OCF growth 5Y20.79%

SARTORIUS AG-VORZUG / SRT3.DE FAQ

What is the ChartMill fundamental rating of SARTORIUS AG-VORZUG (SRT3.DE) stock?

ChartMill assigns a fundamental rating of 2 / 10 to SRT3.DE.


Can you provide the valuation status for SARTORIUS AG-VORZUG?

ChartMill assigns a valuation rating of 1 / 10 to SARTORIUS AG-VORZUG (SRT3.DE). This can be considered as Overvalued.


Can you provide the profitability details for SARTORIUS AG-VORZUG?

SARTORIUS AG-VORZUG (SRT3.DE) has a profitability rating of 3 / 10.


What is the valuation of SARTORIUS AG-VORZUG based on its PE and PB ratios?

The Price/Earnings (PE) ratio for SARTORIUS AG-VORZUG (SRT3.DE) is 50 and the Price/Book (PB) ratio is 6.71.


Can you provide the financial health for SRT3 stock?

The financial health rating of SARTORIUS AG-VORZUG (SRT3.DE) is 1 / 10.